162 related articles for article (PubMed ID: 28953386)
1. Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
Yao L; Mustafa N; Tan EC; Poulsen A; Singh P; Duong-Thi MD; Lee JXT; Ramanujulu PM; Chng WJ; Yen JJY; Ohlson S; Dymock BW
J Med Chem; 2017 Oct; 60(20):8336-8357. PubMed ID: 28953386
[TBL] [Abstract][Full Text] [Related]
2. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
Yang EG; Mustafa N; Tan EC; Poulsen A; Ramanujulu PM; Chng WJ; Yen JJ; Dymock BW
J Med Chem; 2016 Sep; 59(18):8233-62. PubMed ID: 27541357
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
[TBL] [Abstract][Full Text] [Related]
4. Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
Yao L; Ramanujulu PM; Poulsen A; Ohlson S; Dymock BW
Bioorg Med Chem Lett; 2018 Aug; 28(15):2636-2640. PubMed ID: 29945795
[TBL] [Abstract][Full Text] [Related]
5. Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.
Qiu Q; Chi F; Zhou D; Xie Z; Liu Y; Wu H; Yin Z; Shi W; Qian H
J Med Chem; 2023 Apr; 66(8):5753-5773. PubMed ID: 37057760
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y
J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208
[TBL] [Abstract][Full Text] [Related]
7. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
[TBL] [Abstract][Full Text] [Related]
8. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
[TBL] [Abstract][Full Text] [Related]
9. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
[TBL] [Abstract][Full Text] [Related]
10. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
11. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90).
Yao L; Ohlson S; Dymock BW
Bioorg Med Chem Lett; 2018 May; 28(8):1357-1362. PubMed ID: 29545103
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.
Labadie S; Barrett K; Blair WS; Chang C; Deshmukh G; Eigenbrot C; Gibbons P; Johnson A; Kenny JR; Kohli PB; Liimatta M; Lupardus PJ; Shia S; Steffek M; Ubhayakar S; van Abbema A; Zak M
Bioorg Med Chem Lett; 2013 Nov; 23(21):5923-30. PubMed ID: 24042009
[TBL] [Abstract][Full Text] [Related]
14. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
Kulagowski JJ; Blair W; Bull RJ; Chang C; Deshmukh G; Dyke HJ; Eigenbrot C; Ghilardi N; Gibbons P; Harrison TK; Hewitt PR; Liimatta M; Hurley CA; Johnson A; Johnson T; Kenny JR; Bir Kohli P; Maxey RJ; Mendonca R; Mortara K; Murray J; Narukulla R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Waszkowycz B; Zak M
J Med Chem; 2012 Jun; 55(12):5901-21. PubMed ID: 22591402
[TBL] [Abstract][Full Text] [Related]
15. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
16. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
Hagiwara K; Kunishima S; Iida H; Miyata Y; Naoe T; Nagai H
Apoptosis; 2015 Jul; 20(7):975-85. PubMed ID: 25835755
[TBL] [Abstract][Full Text] [Related]
17. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
18. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.
Febvre-James M; Lecureur V; Fardel O
Inflamm Res; 2020 Jan; 69(1):51-62. PubMed ID: 31654094
[TBL] [Abstract][Full Text] [Related]
19. Comparative QSAR model generation using pyrazole derivatives for screening Janus kinase-1 inhibitors.
Sarithamol S; Pushpa VL; Divya V; Manoj KB
Chem Biol Drug Des; 2020 May; 95(5):503-519. PubMed ID: 32022397
[TBL] [Abstract][Full Text] [Related]
20. The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.
Cardoso BA; Belo H; Barata JT; Almeida AM
PLoS One; 2015; 10(12):e0143897. PubMed ID: 26623653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]